NDUFA12 Antibody

Structure and Function of NDUFA12

• Protein Overview:
  NDUFA12 is a 17 kDa accessory subunit of Complex I, encoded by the NDUFA12 gene located on chromosome 12q22 . It contributes to the stability and assembly of Complex I but is not directly involved in catalysis . Mutations in NDUFA12 are linked to mitochondrial disorders like Leigh syndrome, characterized by neurodegeneration and Complex I deficiency .

• Antibody Targeting:
  The NDUFA12 antibody binds to the hydrophilic domain of the protein, which interacts with globular subunits of Complex I. This interaction facilitates structural studies and diagnostic assays .

NDUFA12 Antibody Overview

• Immunogen:
  Antibodies are typically generated using recombinant full-length NDUFA12 protein or synthetic peptides corresponding to its hydrophilic regions (e.g., residues 1–145) .

• Applications:

  • Western Blot (WB): Detects NDUFA12 in mitochondrial lysates and purified Complex I preparations .

  • Immunohistochemistry (IHC): Visualizes mitochondrial localization in tissues (e.g., kidney, liver) .

  • Immunofluorescence (IF): Tracks mitochondrial dynamics in live or fixed cells .

Research Applications

• Mitochondrial Disorders:
  Antibodies detect Complex I defects in Leigh syndrome and isolated Complex I deficiency . A study using the 15793-1-AP antibody identified novel NDUFA12 variants linked to variable clinical manifestations .

• Cancer Research:
  NDUFA12 is a therapeutic target in cancers reliant on oxidative phosphorylation. The ab237731 antibody confirmed that the anticancer compound Ertredin binds NDUFA12, disrupting energy metabolism in glioblastoma and multiple myeloma cells .

• Therapeutic Development:
  A methylated Ertredin analogue, 7MeERT, showed enhanced binding affinity to NDUFA12 (CDOCKER energy: −23.3355 kcal/mol) compared to Ertredin (−17.2322 kcal/mol), correlating with improved antitumor activity .

Clinical and Diagnostic Relevance

• Biomarker Potential:
  NDUFA12 antibodies are used to assess mitochondrial dysfunction in biopsies and cultured cells. For example, HPA039903 validated NDUFA12 expression in human kidney and gastric cancer tissues .

• Therapeutic Monitoring:
  Inhibitors targeting NDUFA12 (e.g., Ertredin and 7MeERT) are under investigation for cancer therapy. Antibodies enable monitoring of drug-protein interactions and treatment efficacy .